The results of the randomized controlled trial -- in which 54% of patients on liraglutide achieved a hemoglobin A1c of less than 7% compared with 43% of those on exenatide -- were presented by John B. Buse, M.D., of the University of North Carolina in Chapel Hill, at the American Diabetes Association meeting and published simultaneously online in The Lancet.
Tuesday, June 09, 2009
Sugar Wars contd. - victory is sweet
NEW ORLEANS, June 8 -- In a head-to-head comparison of two drugs from the new class of glucagon-like peptide-1 (GLP-1) inhibitors, liraglutide once a day improved glycemic control significantly better than did exenatide twice a day, researchers said here.
The results of the randomized controlled trial -- in which 54% of patients on liraglutide achieved a hemoglobin A1c of less than 7% compared with 43% of those on exenatide -- were presented by John B. Buse, M.D., of the University of North Carolina in Chapel Hill, at the American Diabetes Association meeting and published simultaneously online in The Lancet.
The results of the randomized controlled trial -- in which 54% of patients on liraglutide achieved a hemoglobin A1c of less than 7% compared with 43% of those on exenatide -- were presented by John B. Buse, M.D., of the University of North Carolina in Chapel Hill, at the American Diabetes Association meeting and published simultaneously online in The Lancet.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment